IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison Report
Performance
Performance Report
Valiant Laboratories IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 152.46 Cr. The company is based in Mumbai and caters to Pharmaceutical sector. Unistone Capital is the merchant banker of Valiant Laboratories IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 5th June 2023.
Valiant Laboratories IPO posted revenues of ₹ 338.77 crores and PAT of ₹ 29.00 crores in FY25 on annualised basis.
Revenue:
₹ 333.91 Cr.
EBITDA Margin:
10.51
% 
Net Worth: ₹ 100.49 Cr.
Market Capitalisation:
₹ 608.30 Cr.
P/E:
[●]
P/BV: 2.40 times
EV/EBITDA: 19.02 times
Financial results of Valiant Laboratories IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY23 | FY22 | FY21 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 212.75 | 181.81 | 106.31 | ||
| Net Worth | 100.49 | 71.46 | 88.58 | ||
| Total Debt | 59.40 | 60.68 | 0.35 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
333.91 | 291.52 | 182.36 | ||
EBITDA
EBITDA on annualised basis |
35.09 | 42.31 | 50.00 | ||
PAT
PAT on annualised basis |
28.99 | 27.49 | 30.59 | ||
Valiant Laboratories IPO PAT Margin is 8.68 % , ROCE (Return on Capital Employed) is 22.76 % as per latest financial. The below table shows Valiant Laboratories IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY23 | FY22 | FY21 |
|---|---|---|---|
| EBITDA Margin (%) | 10.51 | 14.51 | 27.42 |
| PAT Margin (%) | 8.68 | 9.43 | 16.77 |
| EPS (₹) | 8.91 | 9.52 | 10.83 |
| ROE (%) | 28.85 | 38.47 | 34.53 |
| ROCE (%) | 22.76 | 35.75 | 70.86 |
| ROA (%) | 13.63 | 15.12 | 28.77 |
| Debt to Equity | 0.59 | 0.85 | 0.00 |
The market Capitalisation of Valiant Laboratories IPO is ₹ 608.30 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Valiant Laboratories IPO prospectus highlights an Return on Equity (ROE) of 28.85 % , Return on Assets (ROA) of 13.63 %, and an EBITDA Margin of 10.51 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Valiant Laboratories IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Valiant Laboratories IPO is ₹ 608.30 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Valiant Laboratories IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Valiant Laboratories IPO reported revenue of ₹ 338.77 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Valiant Laboratories IPO provide insights into sales growth, market demand, and business scalability.
Valiant Laboratories recorded an EBITDA of ₹ 35.09 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Valiant Laboratories Profit After Tax (PAT) is ₹ 28.99 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 333.91 Cr.
EBITDA Margin:
10.51
%
Net Worth: ₹ 100.49 Cr.
Market Capitalisation:
₹ 608.30 Cr.
P/E:
[●]
P/BV: 2.40 times
EV/EBITDA: 19.02 times
Valiant Laboratories operates in Pharmaceutical and Manufacturing Of APIs And Bulk Drugs With A Prime Focus On Paracetamol. The Issue is listed on BSE,NSE in Oct, 2023. Valiant Laboratories IPO size was 152.46 with Issue price of 140.00 .
Merchant Banker(s) of Valiant Laboratories IPO: Unistone Capital Private Limited
Valiant Laboratories IPO subscription was 29.76 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Valiant Laboratories IPO listed at a listing price of 169.05 against the offer price of 140.00.
The current market price of Valiant Laboratories is 113.81.
Why Us?
